NUP98/JARID1A as a Recurrent Aberration in Pediatric Acute Megakaryoblastic Leukemia
N/A
30 Years
Both
Leukemia
Trial Information
NUP98/JARID1A as a Recurrent Aberration in Pediatric Acute Megakaryoblastic Leukemia
OBJECTIVES:
- To determine whether NUP98/JARID1A expression is a recurrent translocation in
NUP98-rearranged cases in pediatric acute megakaryoblastic leukemia (AMKL).
- To screen the Children Oncology Group (COG) samples for genetic aberrations in
pediatric AMKL.
OUTLINE: Cryopreserved specimens are analyzed for NUP98 fusion to NSD1, JARID1A, and TOP1,
myeloid/lymphoid or mixed-lineage leukemia (MLL)-rearrangements, and other gene expression
profiling by reverse-transcriptase polymerase chain reaction (RT-PCR) and karyotyping or
fluorescence in situ hybridization ( FISH). Results are then compared with each patient's
outcome data.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Cryopreserved specimens of pediatric patients diagnosed with acute megakaryoblastic
leukemia
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified
Type of Study:
Observational
Study Design:
N/A
Outcome Measure:
NUP98/JARID1A as a recurrent aberration in pediatric AMKL
Safety Issue:
No
Principal Investigator
Soheil Meshinchi, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Fred Hutchinson Cancer Research Center
Authority:
United States: Federal Government
Study ID:
CDR0000736633
NCT ID:
NCT01642069
Start Date:
July 2012
Completion Date:
Related Keywords:
- Leukemia
- childhood acute megakaryocytic leukemia (M7)
- childhood acute myeloid leukemia/other myeloid malignancies
- Leukemia
- Leukemia, Megakaryoblastic, Acute
Name | Location |
|---|
